| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 09/26/2002 | US20020137674 Method of using lectins for prevention and treatment of oral and alimentary tract disorders |
| 09/26/2002 | US20020137673 Factor VII glycoforms |
| 09/26/2002 | US20020137670 Transferrin polycation/DNA complexes for the systemic treatment of tumor diseases with cytotoxic proteins |
| 09/26/2002 | US20020137668 Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers |
| 09/26/2002 | US20020137667 Administering a therapeutically effective amount Trypanosoma cruzi trans-sialidase or a neurotrophic variant; amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, Chagas' disease, peripheral neuropathy, |
| 09/26/2002 | US20020137666 Use of exendins and agonists thereof for the reduction of food intake |
| 09/26/2002 | US20020137212 Recombinant adenovirus expression vector as antitumor agents |
| 09/26/2002 | US20020137210 Method for modifying genetic characteristics of an organism |
| 09/26/2002 | US20020137202 Diagnosis, treatment, and prevention of disorders associated with a FCTRX nucleic acid, polypeptide, or an antibody specific for it |
| 09/26/2002 | US20020137189 Cardiac hypertrophy factor and uses therefor |
| 09/26/2002 | US20020137188 Method of modulating cell survival and reagents useful for same |
| 09/26/2002 | US20020137182 For obtaining and using a polypeptide other than oncogene BCL-2 that affects programmed vertebrate cell death |
| 09/26/2002 | US20020137180 Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof |
| 09/26/2002 | US20020137172 33167, a novel human hydrolase and uses therefor |
| 09/26/2002 | US20020137170 Dual-specificity protein tyrosine phosphatases that dephosphorylate both phosphotyrosine and phosphothreonine/serine residues |
| 09/26/2002 | US20020137168 Designated developmental tyrosine kinases; expressed in multipotential haematopoietic cells, in embryonic stem cells, in brain tissue and in testis, but are not expressed mature lineage-restricted haematopoetic cells |
| 09/26/2002 | US20020137166 ASIP-related proteins |
| 09/26/2002 | US20020137165 As additives for human nutritive compositions or immunotherapeutics for cancer |
| 09/26/2002 | US20020137164 Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof |
| 09/26/2002 | US20020137142 Tango-73 nucleic acids |
| 09/26/2002 | US20020137141 Short peptides from the 'A-region' of protein kinases which selectively modulate protein kinase activity |
| 09/26/2002 | US20020137138 Modulating serotonin activity |
| 09/26/2002 | US20020137137 Genetic engineering; polypeptides |
| 09/26/2002 | US20020137135 Novel NPG-1 gene that is differentially expressed in prostate tumors |
| 09/26/2002 | US20020137134 Genetic engineering; glycoproteins |
| 09/26/2002 | US20020137133 Receptor proteins |
| 09/26/2002 | US20020137132 Genetic engineering; diagnosis of psychological disorders |
| 09/26/2002 | US20020137130 Central nervous system disorder |
| 09/26/2002 | US20020137129 Polypeptides; genetic engineering; drug development |
| 09/26/2002 | US20020137128 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 09/26/2002 | US20020137127 Culture product; polypeptides |
| 09/26/2002 | US20020137126 Al-1 neurotrophic factor, a ligand for an eph related tyrosine kinase receptor |
| 09/26/2002 | US20020137113 Kinase receptor activation assay |
| 09/26/2002 | US20020137100 Method for determining the fertility of mammals, especially of humans |
| 09/26/2002 | US20020137099 Repsiratory system disorders |
| 09/26/2002 | US20020137095 Reelin protein CR-50 epitope region |
| 09/26/2002 | US20020137082 Calibration using chaperone protein |
| 09/26/2002 | US20020137077 Diagnosis, therapy monitoring allergies, infections, cancer, autoimmune disease |
| 09/26/2002 | US20020137063 Diagnosis, therapy of metabolism disorders; polymerase chain reaction |
| 09/26/2002 | US20020137054 AXOR35, a G-protein coupled receptor |
| 09/26/2002 | US20020137050 Hybrid Dna sequence |
| 09/26/2002 | US20020137049 Pablo, a polypeptide that interacts with Bcl-xL, and uses related thereto |
| 09/26/2002 | US20020137044 Novel nucleic acids and polypeptides |
| 09/26/2002 | US20020137042 Isolated human phosphatase proteins, nucleic acid molecules encoding human phosphatase proteins, and uses thereof |
| 09/26/2002 | US20020137030 Method of detection of neoplastic cells |
| 09/26/2002 | US20020137028 Use of neuronal apoptosis inhibitor protein (naip) |
| 09/26/2002 | US20020137023 Methods and compositions for targeting compounds to muscle |
| 09/26/2002 | US20020136800 1-20 wt% of lactase and cutting agent that is 0-4 parts by weight for each part by weight lactase, 1-98 wt% of microcrystalline cellulose, 0-97 wt% of mannitol, and a lubricant to aid in compression |
| 09/26/2002 | US20020136779 Pharmaceutical compound preparation comprising a parathyroid hormone preparation and a calcium/phosphate preparation |
| 09/26/2002 | US20020136774 Luteinizing hormone in an administrable form which ensures an increase in plasma levels for 40-60 hours |
| 09/26/2002 | US20020136769 Nanogel networks including polyion polymer fragments and biological agent compositions thereof |
| 09/26/2002 | US20020136763 Pharmaceutical preparations of glutathione and methods of administration thereof |
| 09/26/2002 | US20020136759 Method of inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules |
| 09/26/2002 | US20020136754 Recombinant bacterial phytases and uses thereof |
| 09/26/2002 | US20020136740 With an antigen that has an epitope of hepatitis c virus |
| 09/26/2002 | US20020136736 Or prophylactically or therapeutically effective fragment thereof in admixture with a pharmaceutically acceptable carrier |
| 09/26/2002 | US20020136730 From coagulase-negative bacteria produced in substantially pure form; use of purified adhesin product as vaccine for production of antibodies effective against binding of homologous bacterial cells to polymeric materials |
| 09/26/2002 | US20020136726 Method for selectively delivering agent to arterial smooth muscle cells in mammal comprising administering agent and substance which selectively binds arterial smooth muscle cell-specific surface molecule selected from ephrin family |
| 09/26/2002 | US20020136725 Administering monoclonal antibodies that bind to a human coagulation factor or cofactor for use as self-limiting inhibitors of thrombosis in combination with plasminogen activators |
| 09/26/2002 | US20020136724 Methods for treating rheumatoid arthritis using IL-17 antagonists |
| 09/26/2002 | US20020136723 Administering methotrexate and an anti-tumor necrosis factor antibody or fragment thereof; rheumatoid arthritis, Crohn's disease, acute and chronic immune diseases |
| 09/26/2002 | US20020136720 Methods of using IMXP-888 and IMXP-888 antagonists |
| 09/26/2002 | US20020136718 Using antibody which catalyzes hydrolysis of beta-amyloid at a predetermined amide linkage |
| 09/26/2002 | US20020136717 Process for screening chemical compounds for modulating the interaction of an EVH1 domain or a protein having an EVH1 domain with an EVH1 binding domain or a protein having an EVH1 binding domain, and a process for detecting said interaction |
| 09/26/2002 | US20020136716 Compositions and methods for altering cell migration |
| 09/26/2002 | US20020136714 Relatedness of human interleukin-1beta convertase gene to a C. elegans cell death gene, inhibitory portions of these genes and uses therefor |
| 09/26/2002 | US20020136713 Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV |
| 09/26/2002 | US20020136712 Bacterial phage associated lysing enzymes for the prophylactic and therapeutic treatment of colonization and infections caused by streptococcus pneumoniae |
| 09/26/2002 | US20020136705 Porcine spinal cord cells and their use in spinal cord repair |
| 09/26/2002 | US20020136704 Method for determining susceptibility of thymus in patient to activation through disruption of sex steroid signaling to thymus |
| 09/26/2002 | US20020136703 Method for regulating IL-10 with IL-9, and applications thereof |
| 09/26/2002 | US20020136701 Applying to area of body having ectoparasites a composition comprising non-volatile surfactants, polar organic compounds, non-volatile fatty alcohols, and non-volatile fatty esters, for a time sufficient to trigger immersion reflex, drying |
| 09/26/2002 | US20020136689 Antibody which specifically binds to prostate stem cell antigen on surface of carcinoma cells and is internalized within carcinoma cells to which it binds |
| 09/26/2002 | US20020135085 Production scale method of forming microparticles |
| 09/26/2002 | DE10110235A1 New protein or peptide comprising epitope of plasminogen activator inhibitor-1, useful for screening substance for treating thromboembolic and cardiovascular diseases, cancer or related diseases |
| 09/26/2002 | CA2469846A1 New interferon beta-like molecules |
| 09/26/2002 | CA2460779A1 Use of gram-negative bacterial membrane fraction for inducing the maturation of dendritic cells |
| 09/26/2002 | CA2442717A1 Methods for restoring cognitive function following systemic stress |
| 09/26/2002 | CA2442036A1 Stress-responsive activator of p300 (strap) protein |
| 09/26/2002 | CA2441902A1 Chimpanzee erythropoietin (chepo) - immunoadhesins |
| 09/26/2002 | CA2441822A1 Asymmetric synthesis of (s, s, r)-(-)-actinonin and its analogs and uses therefor |
| 09/26/2002 | CA2441815A1 Method and composition for treatment of skeletal dysplasias |
| 09/26/2002 | CA2441740A1 Dopaminergic neuronal survival-promoting factors and uses thereof |
| 09/26/2002 | CA2441673A1 Light-emitting fusion proteins and diagnostic and therapeutic methods therefor |
| 09/26/2002 | CA2441510A1 Muteins of hypoxia inducible factor alpha and methods of use thereof |
| 09/26/2002 | CA2441503A1 Method for cleaving human growth hormone gh |
| 09/26/2002 | CA2441388A1 Modified insulin with reduced immunogenicity |
| 09/26/2002 | CA2441291A1 Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
| 09/26/2002 | CA2441155A1 Methods of treating respiratory conditions |
| 09/26/2002 | CA2441147A1 Methods of treating disorders of the eye and surrounding tissue with thymosin .beta.4 (t.beta.4), analogues, isoforms and other derivatives |
| 09/26/2002 | CA2441095A1 Modified interferon beta with reduced immunogenicity |
| 09/26/2002 | CA2440956A1 Oligonucleotides for regulating the gene coding for tnf.alpha. and/or genes controlled thereby and use thereof |
| 09/26/2002 | CA2440844A1 Two-phase processing of thermosensitive polymers for use as biomaterials |
| 09/26/2002 | CA2440749A1 Isolation and purification procedure of vasopeptidase peptide inhibitors |
| 09/26/2002 | CA2440584A1 Isolated human ion channel proteins, nucleic acid molecules encoding human ion channel proteins, and uses thereof |
| 09/26/2002 | CA2440272A1 Nucleic acid-associated proteins |
| 09/26/2002 | CA2439916A1 Compositions and methods for the treatment and clinical remission of psoriasis |
| 09/26/2002 | CA2439757A1 Methods of using neural thread proteins to treat tumors and other conditions requiring the removal or destruction of cells |
| 09/26/2002 | CA2439530A1 Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases |
| 09/26/2002 | CA2439315A1 Compositions useful in gene therapy |